(Total Views: 386)
Posted On: 05/13/2020 9:33:40 AM
Post# of 72446
Pete he did a little more than Kevetrin...
• Identified novel immunomodulatory roles for Brilacidin leading to new indication of use for Brilacidin in inflammatory diseases currently completed phase 2( going for phase 3) clinical trial.
• Hypothesized that Phosphodiesterase is the target for mechanism of action for Host Defense Protein (HDP) mimetic Brilacidin, acting as anti-inflammatory agent. Hypothesis was tested by PDE4 inhibition assay as well as decrease in release of pro-inflammatory cytokines in monocytes, macrophages and animal model in response to Brilacidin was observed.
• Led the team in the development of Brilacidin, which has completed Phase 2 clinical studies for oral mucositis and ulcerative proctitis.
• Identified novel immunomodulatory roles for Brilacidin leading to new indication of use for Brilacidin in inflammatory diseases currently completed phase 2( going for phase 3) clinical trial.
• Hypothesized that Phosphodiesterase is the target for mechanism of action for Host Defense Protein (HDP) mimetic Brilacidin, acting as anti-inflammatory agent. Hypothesis was tested by PDE4 inhibition assay as well as decrease in release of pro-inflammatory cytokines in monocytes, macrophages and animal model in response to Brilacidin was observed.
• Led the team in the development of Brilacidin, which has completed Phase 2 clinical studies for oral mucositis and ulcerative proctitis.
(1)
(0)
Leo Took The Money and Ran
